MA39164A1 - Forme de sel cristalline de (s)-(2-(6-chloro-7-méthyl-1 h-benzo[d]imidazol- 2-yl)-2-méthylpyrrolidin-1-yl)(5-méthoxy-2-(2h-1,2,3-triazol-2-yl)phényl)méthanone comme antagoniste des récepteurs à l'oréxine - Google Patents

Forme de sel cristalline de (s)-(2-(6-chloro-7-méthyl-1 h-benzo[d]imidazol- 2-yl)-2-méthylpyrrolidin-1-yl)(5-méthoxy-2-(2h-1,2,3-triazol-2-yl)phényl)méthanone comme antagoniste des récepteurs à l'oréxine

Info

Publication number
MA39164A1
MA39164A1 MA39164A MA39164A MA39164A1 MA 39164 A1 MA39164 A1 MA 39164A1 MA 39164 A MA39164 A MA 39164A MA 39164 A MA39164 A MA 39164A MA 39164 A1 MA39164 A1 MA 39164A1
Authority
MA
Morocco
Prior art keywords
methylpyrrolidin
methanone
triazol
imidazol
benzo
Prior art date
Application number
MA39164A
Other languages
English (en)
Other versions
MA39164B1 (fr
Inventor
Christoph Boss
Christine Brotschi
Bibia Heidmann
Thierry Sifferlen
Jodi T Williams
Markus Gude
Raumer Markus Von
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of MA39164A1 publication Critical patent/MA39164A1/fr
Publication of MA39164B1 publication Critical patent/MA39164B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne une forme cristalline de chlorhydrate de (s)-(2-(6-chloro-7-méthyl-1 h-benzo[d]imidazol- 2-yl)-2-méthylpyrrolidin-1-yl)(5-méthoxy-2-(2h-1,2,3-triazol-2-yl)phényl)méthanone, des procédés de préparation associés, des compositions pharmaceutiques contenant ladite forme cristalline et son utilisation comme médicament, particulièrement comme antagoniste des récepteurs à l'oréxine.
MA39164A 2013-12-03 2014-12-02 Forme de sel cristalline de (s)-(2-(6-chloro-7-méthyl-1 h-benzo[d]imidazol- 2-yl)-2-méthylpyrrolidin-1-yl)(5-méthoxy-2-(2h-1,2,3-triazol-2-yl)phényl)méthanone comme antagoniste des récepteurs à l'oréxine MA39164B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IB2013060595 2013-12-03
PCT/IB2014/066509 WO2015083071A1 (fr) 2013-12-03 2014-12-02 Forme de sel cristalline de (s)-(2-(6-chloro-7-méthyl-1 h-benzo[d]imidazol- 2-yl)-2-méthylpyrrolidin-1-yl)(5-méthoxy-2-(2h-1,2,3-triazol-2-yl)phényl)méthanone comme antagoniste des récepteurs à l'oréxine

Publications (2)

Publication Number Publication Date
MA39164A1 true MA39164A1 (fr) 2017-08-31
MA39164B1 MA39164B1 (fr) 2019-03-29

Family

ID=52282787

Family Applications (1)

Application Number Title Priority Date Filing Date
MA39164A MA39164B1 (fr) 2013-12-03 2014-12-02 Forme de sel cristalline de (s)-(2-(6-chloro-7-méthyl-1 h-benzo[d]imidazol- 2-yl)-2-méthylpyrrolidin-1-yl)(5-méthoxy-2-(2h-1,2,3-triazol-2-yl)phényl)méthanone comme antagoniste des récepteurs à l'oréxine

Country Status (32)

Country Link
US (2) US9790208B2 (fr)
EP (1) EP3077390B1 (fr)
JP (1) JP6091716B2 (fr)
KR (1) KR101839716B1 (fr)
CN (1) CN105793258B (fr)
AU (1) AU2014358743B2 (fr)
CA (1) CA2929720C (fr)
CL (1) CL2016001348A1 (fr)
CY (1) CY1119687T1 (fr)
DK (1) DK3077390T3 (fr)
EA (1) EA030109B1 (fr)
ES (1) ES2651508T3 (fr)
HK (1) HK1225736B (fr)
HR (1) HRP20171772T1 (fr)
HU (1) HUE034656T2 (fr)
IL (1) IL245922B (fr)
LT (1) LT3077390T (fr)
MA (1) MA39164B1 (fr)
MX (1) MX362701B (fr)
MY (1) MY176244A (fr)
NO (1) NO3077390T3 (fr)
NZ (1) NZ721493A (fr)
PH (1) PH12016500989A1 (fr)
PL (1) PL3077390T3 (fr)
PT (1) PT3077390T (fr)
SA (1) SA516371248B1 (fr)
SG (1) SG11201604541WA (fr)
SI (1) SI3077390T1 (fr)
TW (1) TWI636982B (fr)
UA (1) UA119151C2 (fr)
WO (1) WO2015083071A1 (fr)
ZA (1) ZA201604501B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2855453B1 (fr) * 2012-06-04 2016-12-07 Actelion Pharmaceuticals Ltd. Dérivés de benzimidazole-proline
UA119151C2 (uk) * 2013-12-03 2019-05-10 Ідорсія Фармасьютікалз Лтд КРИСТАЛІЧНА СОЛЬОВА ФОРМА (S)-(2-(6-ХЛОР-7-МЕТИЛ-1H-БЕНЗО[d]ІМІДАЗОЛ-2-ІЛ)-2-МЕТИЛПІРОЛІДИН-1-ІЛ)(5-МЕТОКСИ-2-(2H-1,2,3-ТРИАЗОЛ-2-ІЛ)ФЕНІЛ)МЕТАНОНУ ЯК АНТАГОНІСТ ОРЕКСИНОВОГО РЕЦЕПТОРА
PT3077389T (pt) 2013-12-03 2017-12-15 Idorsia Pharmaceuticals Ltd Forma cristalina de (s)-(2-(6-cloro-7-metil-1hbenzo[d]imidazol-2-il)-2-metilpirrolidin-1-il)(5-metoxi-2-(2h-1,2,3-triazol-2-il)fenil)metanona e a sua utilização como como antagonistas do receptor de orexina
LT3077391T (lt) 2013-12-04 2018-10-25 Idorsia Pharmaceuticals Ltd Benzimidazolo prolino darinių panaudojimas
CN110612291B (zh) 2017-05-03 2024-02-13 爱杜西亚药品有限公司 2-([1,2,3]三唑-2-基)-苯甲酸衍生物的制备
EP4138822A1 (fr) 2020-04-19 2023-03-01 Idorsia Pharmaceuticals Ltd Utilisation médicale de daridorexant
WO2023160004A1 (fr) * 2022-02-25 2023-08-31 南京知和医药科技有限公司 Composé à cycle fusionné ayant une activité analgésique, son procédé de préparation et son utilisation
CN117736193A (zh) * 2023-12-19 2024-03-22 南京知和医药科技有限公司 一种氘代稠环化合物及其制备方法与用途

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3282927A (en) 1964-05-21 1966-11-01 Bristol Myers Co 5-phenyl-4-thiazolylpenicillins
DE60110066T2 (de) 2000-06-16 2006-02-02 Smithkline Beecham P.L.C., Brentford Piperidine zur verwendung als orexinrezeptorantagonisten
KR20030060904A (ko) 2000-10-06 2003-07-16 뉴로젠 코포레이션 Ｃｒｆ 수용체 조절자로서 벤즈이미다졸 및 인돌 유도체
US6943160B2 (en) 2000-11-28 2005-09-13 Smithkline Beecham Plc Morpholine derivatives as antagonists of orexin receptors
US7432270B2 (en) 2001-05-05 2008-10-07 Smithkline Beecham P.L.C. N-aroyl cyclic amines
JP2004534026A (ja) 2001-05-05 2004-11-11 スミスクライン　ビーチャム　パブリック　リミテッド　カンパニー オレキシン受容体アンタゴニストとしてのｎ−アロイルサイクリックアミン誘導体
MXPA03011706A (es) 2001-06-28 2004-03-19 Smithkline Beecham Plc Derivados de n-aroil-amina ciclica como antagonistas del receptor de orexina.
GB0115862D0 (en) 2001-06-28 2001-08-22 Smithkline Beecham Plc Compounds
GB0124463D0 (en) 2001-10-11 2001-12-05 Smithkline Beecham Plc Compounds
GB0127145D0 (en) 2001-11-10 2002-01-02 Smithkline Beecham Compounds
GB0130335D0 (en) 2001-12-19 2002-02-06 Smithkline Beecham Plc Compounds
GB0130393D0 (en) 2001-12-19 2002-02-06 Smithkline Beecham Plc Compounds
EP1539747B1 (fr) 2002-09-18 2006-11-02 Glaxo Group Limited Amines cycliques n-aroyle utilisees comme antagonistes du recepteur d'orexine
GB0225938D0 (en) 2002-11-06 2002-12-11 Glaxo Group Ltd Novel compounds
GB0225944D0 (en) 2002-11-06 2002-12-11 Glaxo Group Ltd Novel compounds
GB0225884D0 (en) 2002-11-06 2002-12-11 Glaxo Group Ltd Novel compounds
AU2005250077B2 (en) 2004-03-01 2011-06-09 Idorsia Pharmaceuticals Ltd Substituted 1,2,3,4-tetrahydroisoquinoline derivatives
CA2644010A1 (fr) 2006-03-15 2007-09-20 Actelion Pharmaceuticals Ltd Derives de tetrahydroisoquinoleine pour renforcer la fonction de la memoire
WO2007135527A2 (fr) * 2006-05-23 2007-11-29 Pfizer Products Inc. Composés de benzimidazolyle
US7994336B2 (en) 2006-08-15 2011-08-09 Actelion Pharmaceuticals Ltd. Azetidine compounds as orexin receptor antagonists
WO2008038251A2 (fr) 2006-09-29 2008-04-03 Actelion Pharmaceuticals Ltd Dérivés du 3-aza-bicyclo[3.1.0]hexane
PE20081229A1 (es) 2006-12-01 2008-08-28 Merck & Co Inc Antagonistas de receptor de orexina de diazepam sustituido
TW200833328A (en) 2006-12-28 2008-08-16 Actelion Pharmaceuticals Ltd 2-aza-bicyclo[3.1.0]hexane derivatives
WO2008087611A2 (fr) 2007-01-19 2008-07-24 Actelion Pharmaceuticals Ltd Dérivés de pyrrolidine et de piperidine
CL2008000836A1 (es) 2007-03-26 2008-11-07 Actelion Pharmaceuticals Ltd Compuestos derivados de tiazolidina, antagonistas del receptor de orexina; composicion farmaceutica que los comprende; y su uso en el tratamiento de neurosis emocional, depresion grave, trastornos psicoticos, alzheimer, parkinson, dolor, entre otras.
JP2010526869A (ja) 2007-05-14 2010-08-05 アクテリオン ファーマシューティカルズ リミテッド ２−シクロプロピル−チアゾール誘導体
WO2008150364A1 (fr) 2007-05-23 2008-12-11 Merck & Co., Inc. Antagonistes du récepteur de la cyclopropylpyrrolidine orexine
GB0712888D0 (en) 2007-07-03 2007-08-15 Glaxo Group Ltd Novel compounds
EP2164847B1 (fr) 2007-07-03 2011-09-14 Actelion Pharmaceuticals Ltd. Composés 3-aza-bicyclo[3.3.0]octane
AR067396A1 (es) 2007-07-03 2009-10-07 Glaxo Group Ltd Compuesto derivado de imidazo(1,2-a)piridin-2-ilmetil piperidina sustituida sal hidrocloruro del mismo uso del compuesto o de la sal hidrocloruro para la preparacion de un medicamento y composiciones farmaceuticas que los comprende
DE602008004265D1 (de) 2007-07-27 2011-02-10 Actelion Pharmaceuticals Ltd Trans-3-aza-bicyclo-ä3.1.0ü-hexan-derivate
NZ583487A (en) 2007-07-27 2011-09-30 Actelion Pharmaceuticals Ltd 2-aza-bicyclo[3.3.0]octane derivatives
CA2699328A1 (fr) 2007-09-24 2009-04-02 Actelion Pharmaceuticals Ltd Pyrrolidines et piperidines en tant qu'antagonistes du recepteur de l'orexine
PE20091010A1 (es) 2007-10-10 2009-08-08 Actelion Pharmaceuticals Ltd Derivados de tetrahidroquinolina
JP2011512400A (ja) 2008-02-21 2011-04-21 アクテリオン ファーマシューティカルズ リミテッド ２−アザ−ビシクロ［２．２．１］ヘプタン誘導体
GB0806536D0 (en) 2008-04-10 2008-05-14 Glaxo Group Ltd Novel compounds
CN102083827A (zh) 2008-07-07 2011-06-01 埃科特莱茵药品有限公司 作为食欲素受体拮抗剂的噻唑烷化合物
WO2010038200A1 (fr) 2008-10-01 2010-04-08 Actelion Pharmaceuticals Ltd Composés d'oxazolidine utilisables en tant qu'antagonistes des récepteurs à orexine
JP2012509911A (ja) 2008-11-26 2012-04-26 グラクソ グループ リミテッド 新規の化合物
JP2012509910A (ja) 2008-11-26 2012-04-26 グラクソ グループ リミテッド 新規の化合物
EP2358713A1 (fr) 2008-11-26 2011-08-24 Glaxo Group Limited Dérivés de l imidazopyridazine agissant en tant qu antagonistes de l orexine
JP2012510493A (ja) 2008-12-02 2012-05-10 グラクソ グループ リミテッド Ｎ−｛［（ｉｒ、４ｓ、６ｒ）−３−（２−ピリジニルカルボニル）−３−アザビシクロ［４．１．０］ヘプタ−４−イル］メチル｝−２−ヘテロアリールアミン誘導体およびその使用
CA2745433A1 (fr) 2008-12-02 2010-06-10 Glaxo Group Ltd. Derives de n-{[(1r,4s,6r)-3-(2-pyridinylcarbonyl)-3-azabicyclo[4.1.0]hept-4-yl]methyl}-2-heteroarylamine et leurs utilisations
GB0823467D0 (en) 2008-12-23 2009-01-28 Glaxo Group Ltd Novel Compounds
CN102459229A (zh) 2009-04-24 2012-05-16 葛兰素集团有限公司 用作食欲肽拮抗剂的3-氮杂二环[4.1.0]庚烷
CA2807000C (fr) 2010-08-24 2018-12-04 Actelion Pharmaceuticals Ltd Derives de proline sulfonamide comme antagonistes des recepteurs de l'orexine
US9242970B2 (en) 2010-11-10 2016-01-26 Actelion Pharmaceuticals Ltd. Lactam derivatives useful as orexin receptor antagonists
ES2541531T3 (es) 2011-02-18 2015-07-21 Actelion Pharmaceuticals Ltd. Nuevos derivados de pirazol e imidazol útiles como antagonistas de orexina
TWI565703B (zh) 2011-11-08 2017-01-11 艾克泰聯製藥有限公司 ２-（１，２，３-三唑-２-基）苯甲醯胺及３-（１，２，３-三唑-２-基）吡啶醯胺衍生物
LT2838900T (lt) * 2012-04-17 2019-11-11 Gilead Sciences Inc Junginiai ir būdai, skirti priešvirusinei terapijai
EP2855453B1 (fr) 2012-06-04 2016-12-07 Actelion Pharmaceuticals Ltd. Dérivés de benzimidazole-proline
CN104703980B (zh) 2012-10-10 2017-09-22 埃科特莱茵药品有限公司 属于[邻双(杂)芳基]‑[2‑(间双(杂)芳基)吡咯烷‑1‑基]甲酮衍生物的食欲素受体拮抗剂
KR20150130413A (ko) 2013-03-12 2015-11-23 액테리온 파마슈티칼 리미티드 오렉신 수용체 길항제로서의 아제티딘 아미드 유도체
PT3077389T (pt) 2013-12-03 2017-12-15 Idorsia Pharmaceuticals Ltd Forma cristalina de (s)-(2-(6-cloro-7-metil-1hbenzo[d]imidazol-2-il)-2-metilpirrolidin-1-il)(5-metoxi-2-(2h-1,2,3-triazol-2-il)fenil)metanona e a sua utilização como como antagonistas do receptor de orexina
UA119151C2 (uk) * 2013-12-03 2019-05-10 Ідорсія Фармасьютікалз Лтд КРИСТАЛІЧНА СОЛЬОВА ФОРМА (S)-(2-(6-ХЛОР-7-МЕТИЛ-1H-БЕНЗО[d]ІМІДАЗОЛ-2-ІЛ)-2-МЕТИЛПІРОЛІДИН-1-ІЛ)(5-МЕТОКСИ-2-(2H-1,2,3-ТРИАЗОЛ-2-ІЛ)ФЕНІЛ)МЕТАНОНУ ЯК АНТАГОНІСТ ОРЕКСИНОВОГО РЕЦЕПТОРА
LT3077391T (lt) 2013-12-04 2018-10-25 Idorsia Pharmaceuticals Ltd Benzimidazolo prolino darinių panaudojimas

Also Published As

Publication number Publication date
AU2014358743B2 (en) 2018-11-29
EA030109B1 (ru) 2018-06-29
NZ721493A (en) 2021-12-24
KR20160093683A (ko) 2016-08-08
TWI636982B (zh) 2018-10-01
US9790208B2 (en) 2017-10-17
CL2016001348A1 (es) 2016-11-25
UA119151C2 (uk) 2019-05-10
CA2929720A1 (fr) 2015-06-11
EP3077390B1 (fr) 2017-09-13
PH12016500989B1 (en) 2016-06-20
JP2016539135A (ja) 2016-12-15
IL245922A0 (en) 2016-08-02
JP6091716B2 (ja) 2017-03-08
MX2016007216A (es) 2016-09-07
MY176244A (en) 2020-07-24
SG11201604541WA (en) 2016-07-28
HRP20171772T1 (hr) 2017-12-29
BR112016012625A8 (pt) 2017-12-26
HK1225736B (zh) 2017-09-15
MX362701B (es) 2019-02-01
US10023560B2 (en) 2018-07-17
TW201605839A (zh) 2016-02-16
ES2651508T3 (es) 2018-01-26
LT3077390T (lt) 2017-11-27
BR112016012625A2 (fr) 2017-08-22
PT3077390T (pt) 2017-12-15
US20160355506A1 (en) 2016-12-08
MA39164B1 (fr) 2019-03-29
AU2014358743A1 (en) 2016-07-14
HUE034656T2 (hu) 2018-02-28
SA516371248B1 (ar) 2018-03-19
CY1119687T1 (el) 2018-04-04
PH12016500989A1 (en) 2016-06-20
CN105793258B (zh) 2018-12-28
KR101839716B1 (ko) 2018-03-16
IL245922B (en) 2019-10-31
NO3077390T3 (fr) 2018-02-10
US20180002317A1 (en) 2018-01-04
CA2929720C (fr) 2019-06-18
DK3077390T3 (da) 2017-11-06
WO2015083071A1 (fr) 2015-06-11
ZA201604501B (en) 2018-12-19
SI3077390T1 (sl) 2017-12-29
CN105793258A (zh) 2016-07-20
EA201600436A1 (ru) 2016-11-30
PL3077390T3 (pl) 2018-02-28
EP3077390A1 (fr) 2016-10-12

Similar Documents

Publication Publication Date Title
MA39164B1 (fr) Forme de sel cristalline de (s)-(2-(6-chloro-7-méthyl-1 h-benzo[d]imidazol- 2-yl)-2-méthylpyrrolidin-1-yl)(5-méthoxy-2-(2h-1,2,3-triazol-2-yl)phényl)méthanone comme antagoniste des récepteurs à l'oréxine
CY1123365T1 (el) Ενωσεις που εχουν δραστικοτητα ανταγωνιστη μουσκαρινικου υποδοχεα και αγωνιστη βητα2 αδρενεργικου υποδοχεα
MA39163A1 (fr) Forme cristalline de (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone et utilisation de celle-ci en tant qu'antagonistes des recepteurs de l'orexine
MA39211A1 (fr) Composés tricycliques comme agents anti-cancers
UA100877C2 (ru) Замещенные спироциклические производные пиперидина как лиганды рецепторов гистамина-3 (h3)
PH12017501424B1 (en) Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
MA35107B1 (fr) Composition pharmaceutique antihypertensive
PE20151535A1 (es) Derivado de dihidropiridazin-3,5-diona
EA201692220A1 (ru) Твердые формы противовирусного соединения
IN2015DN00538A (fr)
EA201590823A1 (ru) 6-((s)-1-{1-[5-(2-гидроксиэтокси)пиридин-2-ил]-1h-пиразол-3-ил}этил)-3h-1,3-бензотиазол-2-он в качестве антагониста tarp-гамма 8-зависимого ampa-рецептора
MA32224B1 (fr) Derives de (pyrazolyl-carbonyl) imidazolidinone pour le traitement de maladies retrovirales
MX2017015047A (es) Compuestos que tienen actividad antagonista del receptor muscarinico y actividad agonista del receptor beta2 adrenergico.
MA50899B1 (fr) Composés utiles pour l'inhibition de cdk7
TR201719911A2 (tr) Raloksi̇fen ve en az bi̇r anti̇psi̇koti̇k ajan i̇çeren kompozi̇syon